A Single-Label Phenylpyrrolocytidine Provides a Molecular Beacon-Like Response Reporting HIV-1 RT Rnase H Activity Alexander S

Total Page:16

File Type:pdf, Size:1020Kb

A Single-Label Phenylpyrrolocytidine Provides a Molecular Beacon-Like Response Reporting HIV-1 RT Rnase H Activity Alexander S 1048–1056 Nucleic Acids Research, 2010, Vol. 38, No. 3 Published online 20 November 2009 doi:10.1093/nar/gkp1022 A single-label phenylpyrrolocytidine provides a molecular beacon-like response reporting HIV-1 RT RNase H activity Alexander S. Wahba1, Abbasali Esmaeili2, Masad J. Damha1 and Robert H. E. Hudson3,* 1Department of Chemistry, McGill University, Montreal, QC, H3A 2K6 Canada, 2Department of Chemistry, University of Birjand, Birjand, Iran and 3Department of Chemistry, University of Western Ontario, London, ON, N6A 5B7 Canada Downloaded from https://academic.oup.com/nar/article/38/3/1048/3112336 by guest on 27 September 2021 Received August 15, 2009; Revised and Accepted October 19, 2009 ABSTRACT identified as a potential target for antiretroviral therapy as it is required for virus infectivity (3); yet there are no 6-Phenylpyrrolocytidine (PhpC), a structurally con- antiRNase H agents in clinical use. Few inhibitors of HIV- servative and highly fluorescent cytidine analog, 1 RNase H were identified until the transition of testing was incorporated into oligoribonucleotides. The methods from gel-based techniques to fluorescent assays PhpC-containing RNA formed native-like duplex amenable to high-throughput screening (HTS) (4–8). The structures with complementary DNA or RNA. The most widely used assay was developed by Parniak and co- PhpC-modification was found to act as a sensitive workers (6) and utilizes a two label, molecular beacon reporter group being non-disruptive to structure and strategy (9) in which the RNA strand is labeled with a 0 the enzymatic activity of RNase H. A RNA/DNA 3 -terminal fluorophore (fluorescein, F) and a DNA 0 hybrid possessing a single PhpC insert was an strand with a quencher (dabcyl, Q) at the 5 -terminus excellent substrate for HIV-1 RT Ribonuclease H (Scheme 1). Fluorescent studies involving nucleic acids most often and rapidly reported cleavage of the RNA strand utilize luminescent tags such as fluorescein or rhodamine with a 14-fold increase in fluorescence intensity. sometimes in combination with a quencher such as The PhpC-based assay for RNase H was superior 4-(dimethylaminoazo)benzene (dabcyl). However, these to the traditional molecular beacon approach in probes can be perturbing to the processes under investiga- terms of responsiveness, rapidity and ease (single tion due to the steric bulk or non-polar groups they intro- label versus dual). Furthermore, the PhpC-based duce to DNA and RNA. Through our own studies on assay is amenable to high-throughput microplate inhibitors of HIV-1 RNase H, we have observed that the assay format and may form the basis for a new 50-dabcyl quencher substantially reduces the catalytic effi- screen for inhibitors of HIV-RT RNase H. ciency of RNase H for its RNA/DNA substrate (SI). The use of intrinsically fluorescent nucleotide base analogs offers a more conservative approach to fluores- INTRODUCTION cence labeling of nucleic acids. Using phosphoramidite The continuing emergence of drug resistant variants of the solid-phase synthesis (10), a fluorescent nucleotide can human immunodeficiency virus (HIV) calls for new tools be incorporated at any position on an oligomer without to combat this epidemic (1). Current clinical treatment of the use of linkers or postsynthetic modifications. In HIV targets essential enzymatic activities associated with addition, the fluorescence intensity of many base the reverse transcription of the viral genome and the modified nucleotides are responsive to changes in their protease activity required for maturation of protein microenvironment, making them reporters for nucleic components of the virus. The most effective control of acid structure and dynamics (11). Despite these advan- the disease has been achieved with combination therapy tages, few fluorescent nucleobase analogs have found targeting these pathways simultaneously. The inclusion of widespread use as a tool for molecular biology, additional targets in a combination drug regimen is highly 2-aminopurine (12) and the pteridine (13) base analogs desirable for potent and long-term disease management. being historically the most important. Recent work from The ribonuclease H (RNase H) activity associated with Tor and others have elegantly demonstrated the value and HIV-reverse transcriptase (HIV-RT) degrades the viral utility in the design and discovery of new fluorescent RNA genome in RNA/DNA hybrids (2), and has been nucleobases (14–17). Despite these and other recent *To whom correspondence should be addressed. Tel: +519 661 2111 (Ext. 86349); Fax: +519 661 3022; Email: [email protected] ß The Author(s) 2009. Published by Oxford University Press. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleic Acids Research, 2010, Vol. 38, No. 3 1049 Table 1. Oligonucleotides used in RNase H assays and Tm data 0 0 a b Name Sequence (5 –3 ) Tm ( C) DNA-1 RNA-2 RNA-1 GAU CUG AGC CUG GGA GCU 65.1 78.5 PhpC-1 GAU CUG AGC CUG GGA G*CU 64.7 78.8 PhpC-2 GAU CUG AGC *CUG GGA GCU 67.5 80.8 aPhpC indicated by *C. b Tm values represent the average of at least 3 independent experiments within 1C. Scheme 1. Representation of fluorescent RNase H assay using a dual label system employing a fluorophore and a quencher. Downloaded from https://academic.oup.com/nar/article/38/3/1048/3112336 by guest on 27 September 2021 Figure 1. The structure of cytidine (C) and unsubstituted pC, with Scheme 2. Reporting via a single fluorescent nucleotide analogs. numbering, compared to PhpC. R = ribose or 20-deoxyribose. *C = 6-phenylpyrrolocytidine (PhpC). advances, there remains a paucity of intrinsically fluores- Table 1), we replaced a single rC nucleoside with PhpC cent cytidine analogs that demonstrate responsiveness to close to the 30-terminus of the RNA/DNA hybrid, their microenvironment and state of hybridization (18) PhpC-1, where it exhibits low fluorescence (quenched thus motivating this work. state) as depicted in Scheme 2. Treatment with HIV-1 The success of a fluorescent nucleobase analog as a RT RNase H generates an RNA tetranucleotide (25) useful reporter resides in its ability to form proper bearing PhpC, and quickly dissociates from its DNA Watson–Crick base pairs, thermostability in double complement with a concomitant dramatic increase in stranded nucleic acids, changes in fluorescence with differ- fluorescence emission. ent hybridization states, recognition of nucleic acid processing/binding enzymes, and its fluorescence intensity. The cytidine analogs pyrrolocytidine (pC, Figure 1) with MATERIALS AND METHODS 6-methyl substitution (MepC) (19–21) satisfies the above 0 0 criteria as a fluorescent reporter, though its fluorescence 5 -O-(4,4 -dimethoxytrityl)-5-iodouridine (2) intensity, as manifested by a modest quantum yield (È), Uridine (2.44 g, 10 mmol) was added to a mixture of lags behind competing chemistries ultimately making iodine (2.54 g, 10 mmol) and silver sulfate (3.12 mg, it a less sensitive probe. One of our laboratories has 10 mmol) in methanol (200 ml) at room temperature shown that the low quantum yield of MepC can be (r.t.). The mixture was stirred for 8 min, after which time remedied by substituting the C-6 position with an the yellow solid was removed by filtration and the filtrate aromatic group without any penalties on sensitivity or was evaporated under reduced pressure. The residue was base pairing fidelity (22–24). co-evaporated with 2 : 1 MeOH/H2O (50 ml) to remove We have now synthesized the ribonucleoside of iodine (which sublimed away) and crystallized from 6-phenylpyrrolocytidine (PhpC, Figure 1) and found water to give pure 5-iodouridine as a white solid (4.44 g, that, like its DNA and PNA homologs, it ranks among 60%). 5-Iodouridine (2.22 g, 6 mmol) was dissolved in the brightest C-analog luminiophores. The fluorescence of pyridine (30 ml) and 4,40-dimethoxytritylchloride (2.64 g, PhpC is sensitive to its microenvironment, and displays 7.8 mmol) was added in four portions during a 4 h a max excitation (360 nm) and max emission (466 nm) period. After an additional 2 h of stirring at r.t. the significantly red-shifted from the absorption of other reaction was quenched by adding 1 ml of 5% NaHCO3 biomolecules. The combination of these properties for 15 min. The solution was concentrated under reduced makes PhpC unique among fluorescent nucleobase pressure, redissolved in 50 ml of dichloromethane (DCM) analogs and has enabled its use as a fluorescent reporter and washed with a solution of 5% NaHCO3 (30 ml). The group in an RNase H assay. Maintaining the same RNA product was further extracted with two 25 ml portions of sequence as the traditional FQ-based assay (6) (RNA-1, DCM, and the combined organic layer was dried over 1050 Nucleic Acids Research, 2010, Vol. 38, No. 3 0 0 0 Mg2SO4 and evaporated to leave the crude product. The (C-4 ), 75.67 (C-2 ), 68.72 (C-3 ), 61.14 (ÀCH2O), 60,29 0 residue was then purified by silica gel column chromatog- (C-5 ), 55.45 (2CH3OAr). ESI-TOF (m/z) 669.2 (M + Na). raphy using an elution gradient with DCM/MeOH/TEA (98 : 1 : 1 to 96 : 3 : 1). Fractions containing 2 were evaporated to give a white foam (3.72 g, 55%). 1H NMR 50-O-(4,40-dimethoxytrityl)-6-PhpC (5) (400 MHz, CDCl3): d = 8.14 (s, 1 H), 7.21–7.42 (m, 11 H), A pressure bottle with compound 4 (0.64 g, 1.0 mmol), 6.84 (m, 4 H), 6.31 (dd, 1J = 6.8 Hz, 2J = 5.9 Hz, 1 H), concentrated NH3OH (4 ml) and MeOH (6 ml) was 4.55 (m, 1 H), 4.07 (m, 1 H), 3.79 (s, 6 H), 3.78 (m, 1 H), stirred at 55C for 24 h.
Recommended publications
  • Role of Citicoline in the Management of Traumatic Brain Injury
    pharmaceuticals Review Role of Citicoline in the Management of Traumatic Brain Injury Julio J. Secades Medical Department, Ferrer, 08029 Barcelona, Spain; [email protected] Abstract: Head injury is among the most devastating types of injury, specifically called Traumatic Brain Injury (TBI). There is a need to diminish the morbidity related with TBI and to improve the outcome of patients suffering TBI. Among the improvements in the treatment of TBI, neuroprotection is one of the upcoming improvements. Citicoline has been used in the management of brain ischemia related disorders, such as TBI. Citicoline has biochemical, pharmacological, and pharmacokinetic characteristics that make it a potentially useful neuroprotective drug for the management of TBI. A short review of these characteristics is included in this paper. Moreover, a narrative review of almost all the published or communicated studies performed with this drug in the management of patients with head injury is included. Based on the results obtained in these clinical studies, it is possible to conclude that citicoline is able to accelerate the recovery of consciousness and to improve the outcome of this kind of patient, with an excellent safety profile. Thus, citicoline could have a potential role in the management of TBI. Keywords: CDP-choline; citicoline; pharmacological neuroprotection; brain ischemia; traumatic brain injury; head injury Citation: Secades, J.J. Role of 1. Introduction Citicoline in the Management of Traumatic brain injury (TBI) is among the most devastating types of injury and can Traumatic Brain Injury. result in a different profile of neurological and cognitive deficits, and even death in the most Pharmaceuticals 2021, 14, 410.
    [Show full text]
  • Drug-Excipient Interaction and Its Importance in Dosage Form
    Journal of Applied Pharmaceutical Science 01 (06); 2011: 66-71 ISSN: 2231-3354 Drug-excipient interacti on and its importance in Received: 29-07-2011 Revised on: 02-08-2011 Accepted: 04-08-2011 dosage form development Nishath Fathima, Tirunagari Mamatha, Husna Kanwal Qureshi, Nandagopal Anitha and Jangala Venkateswara Rao ABSTRACT Excipients are included in dosage forms to aid manufacture, administration or absorption. Although considered pharmacologically inert, excipients can initiate, propagate or participate in Nishath Fathima, Tirunagari chemical or physical interactions with drug compounds, which may compromise the effectiveness Mamatha, Husna Kanwal Qureshi, of a medication. Exicipients are not exquisitely pure. Even for the most commonly used excipients, Nandagopal Anitha and Jangala it is necessary to understand the context of their manufacture in order to identify potential active pharmaceutical ingredients interactions with trace components. Chemical interactions can lead to Venkateswara Rao Sultan-Ul-Uloom College of Pharmacy, degradation of the active ingredient, thereby reducing the amount available for therapeutic effect. Physical interactions can affect rate of dissolution, uniformity of dose or ease of administration. Banjara Hills, Hyderabad - 500034, A.P., India. Key words: Excipient, Drug, Interaction, Physical, Chemical. INTRODUCTION Pharmaceutical dosage form is a combination of active pharmaceutical ingredients (API) and excipients. Excipients are included in dosage forms to aid manufacture, administration or absorption (Crowley and Martini).The ideal excipients must be able to fulfill the important functions i.e. dose, stability and release of API from the formulation. Although considered pharmacologically inert, excipients can initiate, propagate or participate in chemical or physical interactions with drug compounds, which may compromise the effectiveness of a medication.
    [Show full text]
  • DNA Modifications in Models of Alcohol Use Disorders
    Alcohol 60 (2017) 19e30 Contents lists available at ScienceDirect Alcohol journal homepage: http://www.alcoholjournal.org/ DNA modifications in models of alcohol use disorders * Christopher T. Tulisiak a, R. Adron Harris a, b, Igor Ponomarev a, b, a Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, 2500 Speedway, A4800, Austin, TX 78712, USA b The College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, A1900, Austin, TX 78712, USA article info abstract Article history: Chronic alcohol use and abuse result in widespread changes to gene expression, some of which Received 2 September 2016 contribute to the development of alcohol-use disorders (AUD). Gene expression is controlled, in part, by a Received in revised form group of regulatory systems often referred to as epigenetic factors, which includes, among other 3 November 2016 mechanisms, chemical marks made on the histone proteins around which genomic DNA is wound to Accepted 5 November 2016 form chromatin, and on nucleotides of the DNA itself. In particular, alcohol has been shown to perturb the epigenetic machinery, leading to changes in gene expression and cellular functions characteristic of Keywords: AUD and, ultimately, to altered behavior. DNA modifications in particular are seeing increasing research Alcohol fi Epigenetics in the context of alcohol use and abuse. To date, studies of DNA modi cations in AUD have primarily fi fi fi DNA methylation looked at global methylation pro les in human brain and blood, gene-speci c methylation pro les in DNMT animal models, methylation changes associated with prenatal ethanol exposure, and the potential DNA hydroxymethylation therapeutic abilities of DNA methyltransferase inhibitors.
    [Show full text]
  • Mechanism of Mrna Transport in the Nucleus
    Mechanism of mRNA transport in the nucleus Diana Y. Vargas*, Arjun Raj*†, Salvatore A. E. Marras*, Fred Russell Kramer*, and Sanjay Tyagi*‡ *Department of Molecular Genetics, Public Health Research Institute, 225 Warren Street, Newark, NJ 07103; and †Courant Institute of Mathematical Sciences, New York University, 251 Mercer Street, New York, NY 10012 Edited by Joseph G. Gall, Carnegie Institution of Washington, Baltimore, MD, and approved October 4, 2005 (received for review July 5, 2005) The mechanism of transport of mRNA–protein (mRNP) complexes fluorophore whose fluorescence is restored upon hybridization to from transcription sites to nuclear pores has been the subject of a specific nucleic acid sequence. To obtain single-molecule sensi- many studies. Using molecular beacons to track single mRNA tivity, we engineered a host cell line to express an mRNA possessing molecules in living cells, we have characterized the diffusion of multiple molecular beacon binding sites. The binding of many mRNP complexes in the nucleus. The mRNP complexes move freely molecular beacons to each mRNA molecule renders them so by Brownian diffusion at a rate that assures their dispersion intensely fluorescent that individual mRNA molecules can be throughout the nucleus before they exit into the cytoplasm, even detected and tracked. We found that the rate of mRNP diffusion when the transcription site is located near the nuclear periphery. is so fast that mRNP complexes are dispersed throughout the The diffusion of mRNP complexes is restricted to the extranucleo- nucleus soon after their synthesis and well before the onset of lar, interchromatin spaces. When mRNP complexes wander into significant export into the cytoplasm.
    [Show full text]
  • Polymeric Derivative of Cytidine Metabolic Antagonist Polymer-Derivat Von Cytidin Metabolit Antagonist Derive Polymere D’Un Antagoniste Metabolique De La Cytidine
    (19) & (11) EP 1 881 020 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C08G 65/08 (2006.01) A61K 38/00 (2006.01) 11.08.2010 Bulletin 2010/32 C08G 65/333 (2006.01) C08G 69/48 (2006.01) (21) Application number: 06745754.9 (86) International application number: PCT/JP2006/308826 (22) Date of filing: 27.04.2006 (87) International publication number: WO 2006/120914 (16.11.2006 Gazette 2006/46) (54) POLYMERIC DERIVATIVE OF CYTIDINE METABOLIC ANTAGONIST POLYMER-DERIVAT VON CYTIDIN METABOLIT ANTAGONIST DERIVE POLYMERE D’UN ANTAGONISTE METABOLIQUE DE LA CYTIDINE (84) Designated Contracting States: • MASHIBA, Hiroko, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR NIPPON KAYAKU KABUSHIKI KAISHA HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI Tokyo 1150042 (JP) SK TR • YAMAMOTO, Keiichirou, Designated Extension States: c/o NIPPON KAYAKU K.K. AL BA HR MK YU Tokyo 1150042 (JP) • TAKASHIO, Kazutoshi, (30) Priority: 11.05.2005 JP 2005138249 NIPPON KAYAKU K.K. Tokyo 1150042 (JP) (43) Date of publication of application: 23.01.2008 Bulletin 2008/04 (74) Representative: Wablat, Wolfgang Patentanwalt (73) Proprietor: NIPPON KAYAKU KABUSHIKI KAISHA Dr. Dr. W. Wablat Tokyo 102-8172 (JP) Potsdamer Chaussee 48 14129 Berlin (DE) (72) Inventors: • MASUDA, Akira, (56) References cited: c/o NIPPON KAYAKU KABUSHIKI KAISHA EP-A- 0 097 307 EP-A- 0 685 504 Tokyo 1150042 (JP) WO-A-01/21135 WO-A-02/065988 • ONDA, Takeshi, JP-A- 6 206 832 JP-A- 02 300 133 c/o NIPPON KAYAKU KABUSHIKI KAISHA JP-A- 06 206 832 JP-A- 08 048 766 Tokyo 1150042 (JP) JP-A- 2003 524 028 JP-A- 2004 532 289 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Research Progress on Rolling Circle Amplification (RCA)
    pharmaceuticals Review Research Progress on Rolling Circle Amplification (RCA)-Based Biomedical Sensing Lide Gu 1 ID , Wanli Yan 1, Le Liu 1, Shujun Wang 2,3, Xu Zhang 3,4 and Mingsheng Lyu 1,2,3,* 1 College of Marine Life and Fisheries, Huahai Institute of Technology, Lianyungang 222005, China; [email protected] (L.G.); [email protected] (W.Y.); [email protected] (L.L.) 2 Marine Resources Development Institute of Jiangsu, Lianyungang 222005, China; [email protected] 3 Co-Innovation Center of Jiangsu Marine Bio-industry Technology, Huaihai Institute of Technology, Lianyungang 222005, China; [email protected] 4 Verschuren Centre for Sustainability in Energy & the Environment, Cape Breton University, Sydney, NS B1P 6L2, Canada * Correspondence: [email protected] Received: 8 March 2018; Accepted: 10 April 2018; Published: 21 April 2018 Abstract: Enhancing the limit of detection (LOD) is significant for crucial diseases. Cancer development could take more than 10 years, from one mutant cell to a visible tumor. Early diagnosis facilitates more effective treatment and leads to higher survival rate for cancer patients. Rolling circle amplification (RCA) is a simple and efficient isothermal enzymatic process that utilizes nuclease to generate long single stranded DNA (ssDNA) or RNA. The functional nucleic acid unit (aptamer, DNAzyme) could be replicated hundreds of times in a short period, and a lower LOD could be achieved if those units are combined with an enzymatic reaction, Surface Plasmon Resonance, electrochemical, or fluorescence detection, and other different kinds of biosensor. Multifarious RCA-based platforms have been developed to detect a variety of targets including DNA, RNA, SNP, proteins, pathogens, cytokines, micromolecules, and diseased cells.
    [Show full text]
  • Non-Enzymatic Synthesis of the Coenzymes, Uridine Diphosphate
    N O N - E N Z Y M A T I C S Y N T H E S I S OF THE C O E N Z Y M E S , U R I D I N E D I P H O S P H A T E G L U C O S E A N D C Y T I D I N E D I P H O S P H A T E C H O L I N E , A N D O T H E R P H O S P H O R Y L A T E D M E T A B O L I C I N T E R M E D I A T E S A. M A R , J. D W O R K I N , and J. ORO* Department of Biochemical and Biophysical Sciences, University of Houston, Houston, TX 77004, U.S.A. (Received 3 November, 1986) Abstract. The synthesis of uridine diphosphate glucose (UDPG), cytidine diphosphate choline (CDP- choline), glucose-l-phosphate (G1P) and glucose-6-phosphate (G6P) has been accomplished under simulated prebiotic conditions using urea and cyanamide, two condensing agents considered to have been present on the primitive Earth. The synthesis of UDPG was carried out by reacting G1P and UTP at 70 °C for 24 hours in the presence of the condensing agents in an aqueous medium. CDP-choline was obtained under the same conditions by reacting choline phosphate and CTP. G1P and G6P were synthesized from glucose and inorganic phosphate at 70°C for 16 hours.
    [Show full text]
  • Minocycline As a Candidate Treatment
    Behavioural Brain Research 235 (2012) 302–317 Contents lists available at SciVerse ScienceDirect Behavioural Brain Research j ournal homepage: www.elsevier.com/locate/bbr Review Novel therapeutic targets in depression: Minocycline as a candidate treatment a,b c,d c,d f,g Joanna K. Soczynska , Rodrigo B. Mansur , Elisa Brietzke , Walter Swardfager , a,b,e b b Sidney H. Kennedy , Hanna O. Woldeyohannes , Alissa M. Powell , b a,b,e,f,∗ Marena S. Manierka , Roger S. McIntyre a Institute of Medical Science, University of Toronto, Toronto, Canada b Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada c Program of Recognition and Intervention in Individuals in at Risk Mental States (PRISMA), Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil d Interdisciplinary Laboratory of Clinical Neurosciences (LINC), Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil e Department of Psychiatry, University of Toronto, Toronto, Canada f Departments of Pharmacology and Toxicology, University of Toronto, Toronto, Canada g Neuropsychopharmacology Research Group, Sunnybrook Health Sciences Centre, Toronto, Canada h i g h l i g h t s Regional cell loss and brain atrophy in mood disorders may be a consequence of impaired neuroplasticity. Neuroplasticity is regulated by neurotrophic, inflammatory, oxidative, glutamatergic pathways. Abnormalities in these systems are implicated in the pathophysiology of mood disorders. Minocycline exerts effects on neuroplasticity and targets these interacting systems. Evidence indicates that minocycline may be a viable treatment option for mood disorders. a r t i c l e i n f o a b s t r a c t Article history: Mood disorders are marked by high rates of non-recovery, recurrence, and chronicity, which are insuf- Received 1 December 2011 ficiently addressed by current therapies.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • A Fluorescent Probe for Real-Time Isothermal DNA Amplification Jizu Yi, Wandi Zhang and David Y
    Nucleic Acids Research, 2006, Vol. 34, No. 11 e81 doi:10.1093/nar/gkl261 Molecular Zipper: a fluorescent probe for real-time isothermal DNA amplification Jizu Yi, Wandi Zhang and David Y. Zhang* Department of Pathology, Mount Sinai School of Medicine, New York University, One Gustave L. Levy Place, New York, NY 10029, USA Received October 17, 2005; Revised November 21, 2005; Accepted March 31, 2006 ABSTRACT acid amplification technologies that are based on rolling- circle DNA replication used by bacterial phages and plamids Rolling-circle amplification (RCA) and ramification (6). Hybridization of a specially designed single-stranded amplification (RAM, also known as hyperbranched DNA (ssDNA) probe to a target DNA brings the two ends RCA) are isothermal nucleic acid amplification tech- of the probe close to each other. Ligation of these two ends nologies that have gained a great application in in situ by a DNA ligase (7,8) forms a circularized probe (C-probe) signal amplification, DNA and protein microarray that subsequently can be amplified either by RCA with one assays, single nucleotide polymorphism detection, primer (9–11) or by RAM with a pair of primers (one forward as well as clinical diagnosis. Real-time detection of and one reverse primer) (2,4). These technologies are prom- RCA or RAM products has been a challenge because ising for target DNA and protein detections in various assay of most real-time detection systems, including platforms, such as microplate, DNA and protein microarray Taqman and Molecular Beacon, are designed for and in situ signal amplification (12), and may provide a sim- ple, cost-effective, fully automated high-throughput method thermal cycling-based DNA amplification technology.
    [Show full text]
  • Ep 0882734 A2
    Patentamt Europaisches |||| ||| 1 1|| ||| ||| || || || ||| || ||| || || || (19) J European Patent Office Office europeen des brevets (11) EP 0 882 734 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication:ation: (51) |nt. ci.6: C07H 19/167, A61 K 31/70 09.12.1998 Bulletin 1998/50 (21) Application number: 98109318.0 (22) Date of filing: 22.05.1998 (84) Designated Contracting States: • Ishikawa, Tohru AT BE CH CY DE DK ES Fl FR GB GR IE IT LI LU Kanagawa-ken (JP) MC NL PT SE • Ishitsuka, Hideo Designated Extension States: Yokohama-shi, Kanagawa-ken (JP) AL LT LV MK RO SI • Kohchi, Yasunori Fujisawa-shi, Kanagawa-ken (JP) (30) Priority: 02.06.1997 EP 97108791 • Oikawa, Nobuhiro Yokohama-shi, Kanagawa-ken (JP) (71) Applicant: . Shimma, Nobuo F. HOFFMANN-LA ROCHE AG Chigasaki-shi, Kanagawa-ken (JP) 4070 Basel (CH) . Sudaj Hjtomi Fujisawa-shi, Kanagawa-ken 252 (JP) (72) Inventors: • Hattori, Kazuo Kanagawa-ken (JP) (54) 5'-Deoxy-cytidine derivatives (57) Novel 5'-deoxy-cytidine derivatives repre- group which may be substituted for use in medical ther- sented by the general formula (I) apy, especially tumor therapy. (I) wherein R1 is a hydrogen atom or a group easily hydro- lyzable under physiological conditions; R2 is a hydrogen atom, or -CO-OR4 group [wherein R4 is a saturated or branched CM unsaturated, straight or hydrocarbon group < consisting of one to fifteen carbon atoms, or a group of the formula -(CH2)n-Y (in which Y is cyclohexyl or phe- CO nyl; n is an integer from 0 to 4)]; R3 is a hydrogen atom, r»- bromo, iodo, cyano, a
    [Show full text]
  • Rolling Circle Transcription on Smallest Size Double Stranded DNA Minicircles
    Rolling circle transcription on smallest size double stranded DNA minicircles Anders Kristoffersson Populärvetenskaplig sammanfattning Nanoteknik är ett snabbt växande forskningsfält med tillämpningar i vår vardag. Exempel på användningsområden nära oss inbegriper målarfärg, självrengörande fönster och solceller men kanske främst de integrerade kretsar som gör våra datorer och mobiltelefoner möjliga. I detta arbete utreder jag en möjlig komponent till en nanomotor, små DNA cirklar längs vilka ett enzym, ett RNA polymeras rör sig och ger rotationskraft. En sådan motor skulle fungera genom att RNA polymeraset vid transkriptionen rör sig längs med och läser av DNA molekylen. En kopia av DNA koden bildas i form av en RNA molekyl genom hopsättning, eller polymerisering, av fria RNA komponenter. Vid polymeriseringen frigörs energi som driver enzymets rörelse längs den kopierade DNA molekylen. Enzymets rörelse relativt DNA molekylen kan då utnyttjas i en nanomotor. Medan det finns exempel på tidigare användning av RNA polymeras som molekylär motor för att dra last längst DNA molekyler har detta varit för linjära DNA, ingen har hittills tittat på transkription från DNA-cirklar i nanostorlek. I detta arbete har jag konstruerat en storleksserie av små DNA cirklar och genom att studera storleken av de bildade transkriptionsprodukterna visat att stabil transkription från dessa små cirklar är möjligt. Genom att mäta hastigheten för bildandet av RNA-produkten vid transkription från de olika cirklarna relativt ett linjärt DNA konstateras att påverkan av cirkelarisering på transkriptionseffektiviteten är måttlig. Dessa fynd visar att stabil transkription är möjlig även för mycket små cirkulära DNA molekyler och pekar ut vägen mot framtida DNA-nanomotorer. Examensarbete 30 HP Civilingenjörprogrammet Molekylär Bioteknik Uppsala Universitet november 2010 Table of Contents Populärvetenskaplig sammanfattning ...................................................................................................
    [Show full text]